参考文献:
[1] 黄世杰.利拉鲁肽用于减肥的Ⅲ期临床试验获得阳性结果[J].国际药学研究杂志,2014,41(4):428-428.
[2] FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014.
[3] Tsapas A,Karagiannis T,Kakotrichi P,et al.Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis[J]. Diabetes, obesity & metabolism. 2021 May 28.
[4] Domenica M. Rubino et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial. JAMA,January 11, 2022.
[5] Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Sep 15.
[6] Weghuber Daniel,Barrett Timothy,Barrientos-Pérez Margarita et al. Once-Weekly Semaglutide in Adolescents with Obesity.[J] .N Engl J Med, 2022, undefined: undefined.
[7] 《国家药品监督管理局关于调整药物临床试验审评审批程序的公告》(2018 年第 50 号)
联系客服